Pharmaceutical Executive-11-01-2005

Pharmaceutical Executive

Turkey

November 01, 2005

0

0

Sponsored and produced by Focus Reports.

Are We Aligned Yet? A Medicare Part D Roundtable

November 01, 2005

Features

0

0

The most salient feature of the Medicare prescription drug benefit is its uncertainties. That was perhaps the key insight at a roundtable conducted by Pharmaceutical Executive in conjunction with the executive summit "Medicare Part D: Can There Be Alignment Between Government Goals and Industry Opportunity?" cosponsored by this magazine and Model N, a revenue management-solution provider. With a panel that included representatives from pharma, the legal community, prescription benefit managers, and data and service providers, the roundtable looked at the goals of Part D, the threats and opportunities it presents to stakeholders, the skills companies need to develop, and the way the playing field is likely to change over the next few years. What follows is an edited version of the conversation.

Opinion: It's All Relative

November 01, 2005

Washington Report

0

0

PhRMA Guiding Principle number 10 calls for the banishment of reminder ads. While there are many reasons why drug ads truly advance the public health, there are no good arguments for why reminder ads advance public health in any way.

Washington Report: Out of Commission? Crawford Steps Down

November 01, 2005

Washington Report

0

0

The circumstances of Crawford's departure may complicate the process of securing a permanent FDA leader. Congress and HHS are investigating whether his confirmation process failed to uncover important facts.

Global Report: Drug Evaluation in the UK

November 01, 2005

Global Report

0

0

Genentech and Biogen's MabThera has been awaiting NICE appraisal for three years. Merck KGaA's Erbitux has waited two-and-a-half years. A ruling on AstraZeneca's Arimidex isn't expected for more than a year.